Honeywell, Sherwin-Williams Co. Share Gains Lead Dow's 232-Point Jump
Johnson & Johnson (JNJ): Among the Best Long-Term Dividend Stocks to Buy According to Billionaires
Barclays Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $165
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
On the occasion of his first hundred days in office, Trump will hold an event at the White House to promote investment in the USA, with Company Executives from NVIDIA and other companies participating.
US government officials stated that on the 100th day of Trump's second term, over 20 senior business leaders from companies such as NVIDIA, Johnson & Johnson, Toyota, Eli Lilly and Co, and SoftBank Group will visit the White House on Wednesday to participate in an event promoting investment in the USA. A White House official mentioned that Trump plans to advocate for and promote widespread investment in the fields of USA defense, Technology, Medical Care, Consumer products, and investment Funds on the occasion of his hundredth day in office. Despite the concerns of major US enterprises regarding new tariffs, Trump is still trying to attract new investments. Airlines, aerospace companies, Auto Manufacturers, and retailers are all concerned about the impact of tariffs on USA manufacturing.
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $170
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
Plaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Johnson & Johnson Retains 'AAA' Rating at S&P, Credit Outlook Stable
TD Cowen Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $185
HSBC Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Raises Target Price to $184
Will the US Stock Market's Rebound Ignite Your Next Trade?
Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival
Express News | Johnson & Johnson : HSBC Raises Target Price to $184 From $180
Jim Cramer Says You Should Buy Johnson & Johnson (JNJ), Thinks Talc Problems 'Behind It'
J&J Posts Mid-stage Trial Data for Chemotherapy Releasing System in Bladder Cancer
Express News | Johnson & Johnson - Initiates FDA Application for Tar-200 Under Rtor Program
Express News | Johnson & Johnson - Phase 2B Study: 82% Achieve Complete Response, 52.9% Cancer-Free at One Year
Express News | Johnson & Johnson's Tar-200 Monotherapy Demonstrates Highest Complete Response Rate With Sustained Clinical Benefits in Patients With Certain Types of Bladder Cancer